dc.contributor.author |
Melhem N.M. |
dc.contributor.author |
Smith K.N. |
dc.contributor.author |
Huang X.-L. |
dc.contributor.author |
Colleton B.A. |
dc.contributor.author |
Jiang W. |
dc.contributor.author |
Mailliard R.B. |
dc.contributor.author |
Mullins J.I. |
dc.contributor.author |
Rinaldo C.R. |
dc.contributor.editor |
|
dc.date |
2014 |
dc.date.accessioned |
2017-10-18T13:38:22Z |
dc.date.available |
2017-10-18T13:38:22Z |
dc.date.issued |
2014 |
dc.identifier |
10.1016/j.virol.2013.10.015 |
dc.identifier.isbn |
|
dc.identifier.issn |
00426822 |
dc.identifier.uri |
http://hdl.handle.net/10938/20721 |
dc.description.abstract |
It is unclear if HIV-1 variants lose the ability to prime naïve CD8+ cytotoxic T lymphocytes (CTL) during progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution and its impact on primary and memory CD8+ T cell responses pre-seroconversion (SC), post-SC, and during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus variants reached a nadir by 8 years post-SC with development of AIDS, followed by a transient enhancement of anti-HIV-1 CTL responses upon initiation of cART. We show broad and high magnitude primary T cell responses to late variants in pre-SC T cells, comparable to primary anti-HIV-1 responses induced in T cells from uninfected persons. Despite evolutionary changes, CD8+ T cells could still be primed to HIV-1 variants. Hence, vaccination against late, mutated epitopes could be successful in enhancing primary reactivity of T cells for control of the residual reservoir of HIV-1 during cART. © 2013. |
dc.format.extent |
|
dc.format.extent |
Pages: (34-48) |
dc.language |
English |
dc.publisher |
SAN DIEGO |
dc.relation.ispartof |
Publication Name: Virology; Publication Year: 2014; Pages: (34-48); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8+ T cell responses |
dc.type |
Article |
dc.contributor.affiliation |
Melhem, N.M., American University of Beirut, Faculty of Health Sciences, Medical Laboratory Sciences Program, 11-0236 Riad El Solh, 1107-2020 Beirut, Lebanon |
dc.contributor.affiliation |
Smith, K.N., University of Pittsburgh, School of Medicine, Department of Microbiology and Molecular Genetics, Pittsburgh, PA 15213, United States |
dc.contributor.affiliation |
Huang, X.-L., University of Pittsburgh, Graduate School of Public Health, Department of Infectious Diseases and Microbiology, Pittsburgh, PA, 15261, United States |
dc.contributor.affiliation |
Colleton, B.A., Pennsylvania State University, M.S. Hershey Medical Center College of Medicine, Department of Public Health Sciences, Hershey, PA 17033, United States |
dc.contributor.affiliation |
Jiang, W., University of Pittsburgh, Graduate School of Public Health, Department of Infectious Diseases and Microbiology, Pittsburgh, PA, 15261, United States |
dc.contributor.affiliation |
Mailliard, R.B., University of Pittsburgh, Graduate School of Public Health, Department of Infectious Diseases and Microbiology, Pittsburgh, PA, 15261, United States |
dc.contributor.affiliation |
Mullins, J.I., University of Washington, School of Medicine, Department of Microbiology, Seattle, WA 98195-8070, United States |
dc.contributor.affiliation |
Rinaldo, C.R., University of Pittsburgh, Graduate School of Public Health, Department of Infectious Diseases and Microbiology, Pittsburgh, PA, 15261, United States |
dc.contributor.authorAddress |
Rinaldo, C.R.; University of Pittsburgh Graduate School of Public Health, Department of Pathology, 130 DeSoto StreetA419 Crabtree Hall, Pittsburgh, PA 15261, United States; email: rinaldo@pitt.edu |
dc.contributor.authorCorporate |
University: American University of Beirut; Faculty: Faculty of Health Sciences; Department: Medical Laboratory Sciences Program; |
dc.contributor.authorDepartment |
Medical Laboratory Sciences Program |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
rinaldo@pitt.edu |
dc.contributor.faculty |
Faculty of Health Sciences |
dc.contributor.authorInitials |
Melhem, NM |
dc.contributor.authorInitials |
Smith, KN |
dc.contributor.authorInitials |
Huang, XL |
dc.contributor.authorInitials |
Colleton, BA |
dc.contributor.authorInitials |
Jiang, WM |
dc.contributor.authorInitials |
Mailliard, RB |
dc.contributor.authorInitials |
Mullins, JI |
dc.contributor.authorInitials |
Rinaldo, CR |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Rinaldo, CR (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Pathol, 130 DeSoto St,A419 Crabtree Hall, Pittsburgh, PA 15261 USA. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut |
dc.description.cited |
Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128-JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386; Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128-JVI.78.13.7069-7078.2004; Allen TM, 2002, J VIROL, V76, P10507, DOI 10.1128-JVI.76.20.10507-10511.2002; Appay V, 2008, NAT MED, V14, P623, DOI 10.1038-nm.f.1774; Baker BM, 2009, EXPERT OPIN BIOL TH, V9, P55, DOI 10.1517-14712590802571928 ; Bangham CRM, 2009, EUR J IMMUNOL, V39, P1700, DOI 10.1002-eji.200939451; Barouch DH, 2010, ANNU REV MED, V61, P153, DOI 10.1146-annurev.med.042508.093728; Barouch DH, 2003, J VIROL, V77, P8729, DOI 10.1128-JVI.77.16.8729-8735.2003; Berger CT, 2011, J VIROL, V85, P9334, DOI 10.1128-JVI.00460-11; Bihl F, 2006, J IMMUNOL, V176, P4094; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038-nm0297-205; Buchli R, 2005, BIOCHEMISTRY-US, V44, P12491, DOI 10.1021-bi050255v; Buseyne F, 2001, INT IMMUNOL, V13, P941, DOI 10.1093-intimm-13.7.941; Casazza JP, 2005, J VIROL, V79, P3653, DOI 10.1128-JVI.79.6.3653-3663.2005; Chen HB, 2012, NAT IMMUNOL, V13, P691, DOI 10.1038-ni.2342; Colleton BA, 2009, J VIROL, V83, P6288, DOI 10.1128-JVI.02611-08; Corbeau P, 2011, BLOOD, V117, P5582, DOI 10.1182-blood-2010-12-322453; Corey L, 2009, AIDS, V23, P3, DOI 10.1097-QAD.0b013e32830e6d6d; Davenport MP, 2007, CURR OPIN IMMUNOL, V19, P294, DOI 10.1016-j.coi.2007.04.001; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016-j.immuni.2007.08.010; Detels R, 2012, PUBLIC HEALTH, V126, P196, DOI 10.1016-j.puhe.2011.11.013; Draenert R, 2004, J EXP MED, V199, P905, DOI 10.1084-jem.20031982; Fan Z, 2007, CLIN VACCINE IMMUNOL, V14, P1127, DOI 10.1128-CVI.00141-07; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128-JVI.78.5.2187-2200.2004; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016-0090-1229(90)90096-9; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038-nri2357; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007-s00251-008-0341-z; Huang XL, 2008, J LEUKOCYTE BIOL, V83, P1530, DOI 10.1189-jlb.1107795; Janbazian L, 2012, J IMMUNOL, V188, P1156, DOI 10.4049-jimmunol.1102610; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084-jem.20040511; Kalams SA, 1999, J VIROL, V73, P6721; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038-nm1520; KOUP RA, 1994, J VIROL, V68, P4650; Ladell K, 2013, IMMUNITY, V38, P425, DOI 10.1016-j.immuni.2012.11.021; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038-nm992; Liu JY, 2009, NATURE, V457, P87, DOI 10.1038-nature07469; Liu Y, 2011, PLOS ONE, V6, DOI 10.1371-journal.pone.0015639; Liu Y, 2007, J VIROL, V81, P12179, DOI 10.1128-JVI.01277-07; Liu Y, 2006, J VIROL, V80, P9519, DOI 10.1128-JVI.00575-06; Malaspina Angela, 2011, Vaccine, V29, P4647, DOI 10.1016-j.vaccine.2011.04.035; Malhotra U, 2007, J VIROL, V81, P5225, DOI 10.1128-JVI.02564-06; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016-S0140-6736(08)61592-5; Nielsen M, 2007, PLOS ONE, V2, DOI 10.1371-journal.pone.0000796; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038-nm0502-493; Pandrea I, 2011, PLOS PATHOG, V7, DOI 10.1371-journal.ppat.1002170; PARKER KC, 1994, J IMMUNOL, V152, P163; Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016-j.immuni.2004.10.010; Prlic M, 2007, CURR OPIN IMMUNOL, V19, P315, DOI 10.1016-j.coi.2007.04.010; Reynolds MR, 2008, J EXP MED, V205, P2537, DOI 10.1084-jem.20081524; Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111-j.1365-2796.2008.02047.x; Rinaldo CR, 2000, J VIROL, V74, P4127, DOI 10.1128-JVI.74.9.4127-4138.2000; Rolland M, 2008, PLOS ONE, V3, DOI 10.1371-journal.pone.0001424; Rosario M, 2010, EUR J IMMUNOL, V40, P1973, DOI 10.1002-eji.201040344; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073-pnas.0611244104; SCHENKER EL, 1993, CYTOMETRY, V14, P307, DOI 10.1002-cyto.990140311; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126-science.283.5403.857; Schneider Eileen, 2008, Morbidity and Mortality Weekly Report, V57, P1; Shankarappa R, 1999, J VIROL, V73, P10489; Shin H, 2007, J EXP MED, V204, P941, DOI 10.1084-jem.20061937; Shriner D, 2004, GENETICS, V167, P1573, DOI 10.1534-genetics.103.023382; Tenzer S, 2009, NAT IMMUNOL, V10, P636, DOI 10.1038-ni.1728; Turnbull EL, 2009, J IMMUNOL, V182, P7131, DOI 10.4049-jimmunol.0803658; van Bockel DJ, 2011, J IMMUNOL, V186, P359, DOI 10.4049-jimmunol.1001807; Vezys V, 2006, J EXP MED, V203, P2263, DOI 10.1084-jem.20060995; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073-pnas.0407192101; Yokomaku Y, 2004, J VIROL, V78, P1324, DOI 10.1128-JVI.78.3.1324-1332.2004; Yusim S., 2004, HIV IMMUNOLOGY HIV S, P25; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038-nature07657 |
dc.description.citedCount |
|
dc.description.citedTotWOSCount |
2 |
dc.description.citedWOSCount |
1 |
dc.format.extentCount |
15 |
dc.identifier.articleNo |
|
dc.identifier.coden |
VIRLA |
dc.identifier.pubmedID |
24503065 |
dc.identifier.scopusID |
84890810921 |
dc.identifier.url |
|
dc.publisher.address |
525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
R01-AI-40388, NIH, National Institutes of Health |
dc.relation.ispartofFundingAgency |
R37-AI-41870, NIH, National Institutes of Health |
dc.relation.ispartofFundingAgency |
U01-AI-35041, NIH, National Institutes of Health |
dc.relation.ispartofFundingAgency |
T32-AI065380, NIH, National Institutes of Health |
dc.relation.ispartOfISOAbbr |
Virology |
dc.relation.ispartOfIssue |
|
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Virology |
dc.relation.ispartofPubTitleAbbr |
Virology |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
|
dc.source.ID |
WOS:000331485500005 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Autologous viral variants |
dc.subject.otherAuthKeyword |
CART |
dc.subject.otherAuthKeyword |
HIV-1 |
dc.subject.otherAuthKeyword |
Memory T cell responses |
dc.subject.otherAuthKeyword |
Primary T cell responses |
dc.subject.otherChemCAS |
abacavir, 136470-78-5, 188062-50-2 |
dc.subject.otherChemCAS |
efavirenz, 154598-52-4 |
dc.subject.otherChemCAS |
lamivudine, 134678-17-4, 134680-32-3 |
dc.subject.otherChemCAS |
nelfinavir, 159989-64-7, 159989-65-8 |
dc.subject.otherChemCAS |
saquinavir, 127779-20-8, 149845-06-7 |
dc.subject.otherChemCAS |
zidovudine, 30516-87-1 |
dc.subject.otherIndex |
abacavir |
dc.subject.otherIndex |
antiretrovirus agent |
dc.subject.otherIndex |
CD8 antigen |
dc.subject.otherIndex |
efavirenz |
dc.subject.otherIndex |
efavirenz plus emtricitabine plus tenofovir disoproxil |
dc.subject.otherIndex |
epitope |
dc.subject.otherIndex |
lamivudine |
dc.subject.otherIndex |
nelfinavir |
dc.subject.otherIndex |
saquinavir |
dc.subject.otherIndex |
zidovudine |
dc.subject.otherIndex |
acquired immune deficiency syndrome |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
antigen specificity |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
CD8+ T lymphocyte |
dc.subject.otherIndex |
genetic conservation |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
human cell |
dc.subject.otherIndex |
Human immunodeficiency virus 1 |
dc.subject.otherIndex |
Human immunodeficiency virus 1 infection |
dc.subject.otherIndex |
immunoreactivity |
dc.subject.otherIndex |
memory T lymphocyte |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
seroconversion |
dc.subject.otherIndex |
Autologous viral variants |
dc.subject.otherIndex |
cART |
dc.subject.otherIndex |
HIV-1 |
dc.subject.otherIndex |
Memory T cell responses |
dc.subject.otherIndex |
Primary T cell responses |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Anti-HIV Agents |
dc.subject.otherIndex |
CD8-Positive T-Lymphocytes |
dc.subject.otherIndex |
Cohort Studies |
dc.subject.otherIndex |
Epitopes, T-Lymphocyte |
dc.subject.otherIndex |
Evolution, Molecular |
dc.subject.otherIndex |
Histocompatibility Antigens Class I |
dc.subject.otherIndex |
HIV Infections |
dc.subject.otherIndex |
HIV-1 |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
T-Lymphocytes |
dc.subject.otherIndex |
Viral Proteins |
dc.subject.otherKeywordPlus |
MULTICENTER AIDS COHORT |
dc.subject.otherKeywordPlus |
ACTIVE ANTIRETROVIRAL THERAPY |
dc.subject.otherKeywordPlus |
HIV-1 INFECTION |
dc.subject.otherKeywordPlus |
LYMPHOCYTE ESCAPE |
dc.subject.otherKeywordPlus |
FUNCTIONAL-AVIDITY |
dc.subject.otherKeywordPlus |
PEPTIDE-BINDING |
dc.subject.otherKeywordPlus |
DENDRITIC CELLS |
dc.subject.otherKeywordPlus |
IMMUNE CONTROL |
dc.subject.otherKeywordPlus |
ANTIGEN |
dc.subject.otherKeywordPlus |
VACCINE |
dc.subject.otherWOS |
Virology |